Fennec Pharmaceuticals Inc. reported a fourth-quarter loss that significantly undershot Wall Street expectations, posting GAAP earnings of negative $0.17 per share against a consensus estimate of $0.04 per share. The company recorded a net loss of $5.1M for the quarter ended December 2025.
The pediatric oncology-focused pharmaceutical company generated $13.8M in revenue for the quarter, marking growth of 75.0% year-over-year. Product sales, net led the company’s performance with $13.8M in revenue, up 75.0% compared to the same period last year. Net product sales reached 14 millions for the quarter as the company continued commercializing its specialty pharmaceutical products.
Fennec operated 31,175 weighted-average shares outstanding on a diluted basis at quarter end. The substantial earnings miss comes despite the strong top-line growth, suggesting increased operating expenses or investment in the company’s commercial infrastructure as it scales its product portfolio in the competitive pediatric oncology market.
A detailed analysis of Fennec Pharmaceuticals Inc.’s quarter follows shortly on AlphaStreet.
This article was generated with the assistance of AI technology and reviewed for accuracy. AlphaStreet may receive compensation from companies mentioned in this article. This content is for informational purposes only and should not be considered investment advice.
The post Fennec Pharmaceuticals Inc. (FENC) Misses Q4 EPS Estimates first appeared on Alphastreet.
